Your shopping cart is currently empty

Ozanimod hydrochloride (RPC-1063 hydrochloride) is an orally available, selective and potent sphingosine 1-phosphate (S1P) receptor modulator that shows high affinity for S1P1 and S1P5.Ozanimod has potential anticancer activity and can be used in the study of multiple sclerosis (MS), ulcerative multiple sclerosis (UMS), and other diseases. (MS), ulcerative colitis, coronavirus infections and myelodysplasia.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $147 | In Stock | In Stock | |
| 25 mg | $297 | In Stock | In Stock | |
| 50 mg | $479 | In Stock | In Stock | |
| 100 mg | $689 | In Stock | In Stock | |
| 200 mg | $973 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $108 | In Stock | In Stock |
| Description | Ozanimod hydrochloride (RPC-1063 hydrochloride) is an orally available, selective and potent sphingosine 1-phosphate (S1P) receptor modulator that shows high affinity for S1P1 and S1P5.Ozanimod has potential anticancer activity and can be used in the study of multiple sclerosis (MS), ulcerative multiple sclerosis (UMS), and other diseases. (MS), ulcerative colitis, coronavirus infections and myelodysplasia. |
| Targets&IC50 | S1P1 receptor:1.03 nM (EC50), S1P5 receptor:8.6 nM (EC50) |
| In vitro | Ozanimod hydrochloride, as a sphingosine-1-phosphate (S1P) receptor modulator, selectively binds with high affinity to S1P receptor subtypes 1 (S1P1) and S1P5[1]. |
| In vivo | In the experimental autoimmune encephalomyelitis (EAE) model, Ozanimod hydrochloride (0.05, 0.2, or 1 mg/kg; oral gavage; once daily; for 14 consecutive days) alleviated weight loss, with significantly reduced terminal disease scores observed in the 0.2 and 1 mg/kg dose groups. Moreover, cell counts were significantly reduced in all dose groups[1]. |
| Synonyms | RPC-1063 hydrochloride, BMS-986374 hydrochloride |
| Molecular Weight | 440.92 |
| Formula | C23H25ClN4O3 |
| Cas No. | 1618636-37-5 |
| Smiles | N(CCO)[C@@H]1C=2C(=C(C=CC2)C=3N=C(ON3)C4=CC(C#N)=C(OC(C)C)C=C4)CC1.Cl |
| Storage | keep away from direct sunlight,keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 150 mg/mL (340.2 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (11.34 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.